151 related articles for article (PubMed ID: 23687785)
21. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
22. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
23. [Targeted therapy and breast cancer: state of the art].
Molnar-Stanciu D; Guimas V; Bensalem A; Thiery-Vuillemin A
Pathol Biol (Paris); 2012 Aug; 60(4):254-63. PubMed ID: 22728007
[TBL] [Abstract][Full Text] [Related]
24. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
25. Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.
Soleja M; Rimawi MF
Curr Probl Cancer; 2016; 40(2-4):117-129. PubMed ID: 27839746
[TBL] [Abstract][Full Text] [Related]
26. Fifteen years of anti-HER2 therapy.
Davidson NE
Oncology (Williston Park); 2013 Mar; 27(3):151. PubMed ID: 23687781
[No Abstract] [Full Text] [Related]
27. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
28. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
[No Abstract] [Full Text] [Related]
29. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Zhang B; Hurvitz S
Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
[TBL] [Abstract][Full Text] [Related]
32. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
Bedard PL; Piccart-Gebhart MJ
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
34. [Anti-Her2 therapy in breast cancer].
Kuroi K
Nihon Rinsho; 2012 Sep; 70 Suppl 7():606-13. PubMed ID: 23350472
[No Abstract] [Full Text] [Related]
35. Why your preferred targeted drugs may become unaffordable.
Piccart MJ
Cancer Res; 2013 Oct; 73(19):5849-51. PubMed ID: 24062313
[TBL] [Abstract][Full Text] [Related]
36. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Ito Y
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
[No Abstract] [Full Text] [Related]
37. Targeted Therapy in HER2-Positive Breast Cancer.
Thill M; Kraft C; Friedrich M
Oncol Res Treat; 2016; 39(5):295-302. PubMed ID: 27173915
[TBL] [Abstract][Full Text] [Related]
38. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
39. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
40. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
Lehr HA; Schaefer SC; Delaloye JF
Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
